GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 23, 2002, 19:00:33 ; Search time 179 Seconds
(without alignments)
3347.504 Million cell updates/sec

Title: US-09-728-446-819
Perfect score: 349
Sequence: 1 tattatatgtaagtacnctg.....gnnttggcctttgaaggttg 349

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_032802:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	130.6	37.4	1209	19	AAV32579	Human high voltage
	2	130.6	37.4	1393	18	AAT94469	Human Fchd545 gene
	3	130.6	37.4	1393	21	AAZ50709	Nucleotide sequenc
	4	130.6	37.4	1414	20	AAX57719	Voltage-dependent
	5	121	34.7	1062	23	AAS74839	DNA encoding novel
	6	105	30.1	1672	23	AAS74840	DNA encoding novel
	7	77.8	22.3	435	21	AAC01263	Human secreted pro
	8	57.8	16.6	473	23	AAS74836	DNA encoding novel
	9	51	14.6	26698	17	AAT08126	Mouse syndecan-1 g
	10	51	14.6	26700	15	AAQ67902	Syndecan gene. Mu
	11	51	14.6	26700	19	AAV15946	Mouse syndecan gen
	12	51	14.6	26700	20	AAV81283	Mouse syndecan-1 e
c	13	50	14.3	178	20	AAX85695	Novel cDNA sequenc
c	14	50	14.3	5889	20	AAV84328	Mouse A-myb genomi
	15	50	14.3	6094	22	AAF63435	Murine CD39-L2 gen
c	16	49.4	14.2	14775	24	ABI99535	Mouse ischaemic co
	17	49.4	14.2	36901	20	AAZ23892	Murine LOBO genomi
	18	49.4	14.2	38886	20	AAZ23897	Murine LOBO homolo
	19	49.2	14.1	14775	24	ABI99535	Mouse ischaemic co
c	20	48.4	13.9	2623	22	AAD17484	Mouse glucokinase
	21	47.8	13.7	5318	21	AAC77094	Human ORFX ORF2649
c	22	46.8	13.4	35828	21	AAA29063	Murine TGF-beta bi
c	23	46.8	13.4	90050	21	AAZ91925	Wild type (C57BL/6
c	24	46.2	13.2	1459	22	AAF55245	Nucleotide sequenc
	25	45.2	13.0	6789	22	AAF63436	Murine CD39-L4 gen
c	26	45.2	13.0	8212	24	ABI99884	Mouse ischaemic co
	27	45.2	13.0	13499	24	AAD22571	Mouse FDRG (fibrin
	28	44.6	12.8	48974	20	AAX55300	Mouse Presenilin-1
	29	44.2	12.7	60	22	AAF81610	OST7 clone fragmen
	30	44.2	12.7	60	22	AAF81611	Murine 45S pre rRN
c	31	43.6	12.5	4048	22	AAH24196	Mouse ageing inhib
	32	43.6	12.5	49999	20	AAZ23891	Murine LOBO genomi
	33	43.6	12.5	49999	20	AAZ23896	Murine LOBO homolo
c	34	43	12.3	433	22	ABA77130	Proliferative glom
	35	42.8	12.3	13146	18	AAT96719	Murine RENT1 genom
c	36	42.6	12.2	1104	20	AAZ10360	Partial genomic se
	37	42.6	12.2	4612	24	ABI99462	Mouse ischaemic co
c	38	42.4	12.1	6480	19	AAT99572	Mouse Friend virus
	39	42	12.0	4580	17	AAT32034	Proliferation-inhi
	40	42	12.0	90050	21	AAZ91925	Wild type (C57BL/6
c	41	41.4	11.9	8114	24	AAS15581	pPL5 fragment cont
c	42	41.4	11.9	11689	21	AAC87705	Mouse plakophilin-
	43	41.2	11.8	467	23	AAS74838	DNA encoding novel
c	44	41.2	11.8	1445	22	AAC82696	Murine variant Zal
c	45	40.6	11.6	37339	22	AAS15612	Mouse osteocalcin

ALIGNMENTS

RESULT 1
AAV32579
ID AAV32579 standard; cDNA; 1209 BP.
XX
AC AAV32579;
XX
DT 23-SEP-1998 (first entry)
XX
DE Human high voltage-dependent anion channel cDNA.
XX
KW HACH; human high voltage-dependent anion channel; genomic mapping;
KW drug screening; proliferation disease; rheumatoid arthritis; tumour;
KW immuno-diagnosis; hypothalamus cDNA library; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 94..945
FT /*tag= a
FT /product= HACH
XX
PN US5780235-A.
XX
PD 14-JUL-1998.
XX
PF 04-OCT-1996; 96US-0726227.
XX
PR 04-OCT-1996; 96US-0726227.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Bandman O, Hillman JL;

```
XX
DR   WPI; 1998-413045/35.
DR   P-PSDB; AAW48908.
XX
PT   New high voltage dependent anion channel protein and related nucleic
PT   acid - vectors and transformed cells, useful for diagnosis and
PT   treatment of tumours and other proliferative diseases
XX
PS   Claim 3; Fig 1A-1B; 25pp; English.
XX
CC   The present sequence represents the Human high voltage-dependent anion
CC   channel (HACH) cDNA isolated from a hypothalamus cDNA library.  Cells
CC   transformed with HACH cDNA can be used to produce recombinant HACH
CC   protein.  HACH cDNA or its fragments, are claimed to be useful for
CC   detecting and/or quantifying HACH gene expression (for diagnosis or
CC   monitoring), as probes and primers for detecting genomic sequences
CC   encoding HACH or related proteins.  They are also claimed to be useful
CC   in drug screening and genomic mapping.  HACH protein or its activity
CC   is claimed to be useful for inhibiting growth of tumours and for
CC   treating other cell proliferation diseases, e.g. rheumatoid arthritis.
CC   HACH protein and its fragments are also claimed to be useful for
CC   screening binding agents for the protein, potential therapeutic
CC   agents, and to raise antibodies.  Antibodies can be useful for
CC   diagnosing or monitoring HACH-related disorders, also therapeutically,
CC   in competitive drug screens, and for affinity purification of the
CC   HACH protein from natural sources.
XX
SQ   Sequence 1209 BP; 342 A; 233 C; 301 G; 332 T; 1 other;

  Query Match             37.4%;  Score 130.6;  DB 19;  Length 1209;
  Best Local Similarity   72.6%;  Pred. No. 1.4e-34;
  Matches  191;  Conservative    0;  Mismatches   68;  Indels    4;  Gaps    3;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || ||||||||||| |   |||  || |||  |||||| |||
Db     280 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGACAATACTCTAGGG 339

Qy     148 ACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||| ||||||  |  ||||||| ||||| |||||||||| ||||||||
Db     340 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTGACTCTTGATACCAT 398

Qy     208 ATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTTTCCCGGCCTCCTATTGCCNGNAT 267
           |||| ||||   | |    |       ||||  |  ||   |||||||||   | | ||
Db     399 ATTTGTACCGAACACAGGAA--AGAAGAGTGGGAAATTGAAGGCCTCCTATAAACGGGAT 456

Qy     268 TGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTTCTGGACCGACCATCTATGGCT-G 326
           || |  | | | ||||||||||||||| |  |||||||||||| |||||||||||| |
Db     457 TGTTTTAGTGTTGGCAGTAATGTTGATATAGATTTTTCTGGACCAACCATCTATGGCTGG 516

Qy     327 TCTGNNTTGGCCTTTGAAGGTTG 349
           |||  |||||||| ||||| ||
Db     517 GCTGTGTTGGCCTTCGAAGGGTG 539


RESULT 2
AAT94469
ID   AAT94469 standard; cDNA; 1393 BP.
XX
AC   AAT94469;
XX
DT   03-MAR-1998  (first entry)
XX
DE   Human Fchd545 gene differentially regulated in endothelial cells.
XX
KW   Fchd545 gene; differential expression; endothelial cell; human;
KW   shear stress; cardiovascular disease; atherosclerosis; ischaemia;
KW   reperfusion; hypertension; restenosis; arterial inflammation;
KW   therapy; diagnosis; drug screening; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             90..941
FT                   /*tag= a
XX
PN   WO9730065-A1.
XX
PD   21-AUG-1997.
XX
PF   14-FEB-1997;   97WO-US02291.
XX
PR   13-FEB-1997;   97US-0799910.
PR   16-FEB-1996;   96US-0011787.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Falb DA;
XX
DR   WPI; 1997-424966/39.
DR   P-PSDB; AAW36004.
XX
PT   New genes differentially expressed in cardiovascular disease - used
PT   for diagnosis, drug screening and treatment of cardiovascular
PT   disease, e.g. atherosclerosis, restenosis, hypertension, etc
XX
PS   Claim 1; Fig 3; 163pp; English.
XX
CC   Fchd545 is a novel human gene that is down-regulated in endothelial
CC   cells subjected to laminar shear stress.  Differential display was
CC   used to detect genes that are differentially expressed in
CC   endothelial cells subjected to fluid shear stress in vitro.  Shear
CC   stress is thought to be responsible for the prevelence of
CC   atherosclerotic lesions in areas of unusual circulatory flow.  Also
CC   identified were novel gene fchd531 (see AAT94467), which is
CC   up-regulated in endothelial cells under laminar and turbulent shear
CC   stress, and fchd540 (see AAT94468), which is up-regulated in
CC   endothelial cells under laminar shear stress.  These genes provide a
CC   fingerprint for the study of cardiovascular diseases, including
CC   atherosclerosis, ischaemia/reperfusion, hypertension and restenosis.
CC   Methods are provided for the diagnosis, monitoring in clinical
CC   trials, screening for therapeutically effective compounds, and
CC   treatment of cardiovascular diseases based on discoveries regarding
CC   the expression patterns of novel genes fchd531, fchd540, fchd545,
CC   fchd602 (see AAT94470) and fchd605 (see AAT96671).  The fchd545 gene,
CC   deposited as ATCC 69974, encodes a transmembrane protein (see
CC   AAW36004) that provides an excellent target for detection of
CC   cardiovascular disease states in diagnostic systems.  The fchd545
CC   gene is also expressed in the human heart, smooth muscle and
CC   testis.
XX
SQ   Sequence 1393 BP; 386 A; 269 C; 334 G; 404 T; 0 other;

  Query Match             37.4%;  Score 130.6;  DB 18;  Length 1393;
  Best Local Similarity   72.6%;  Pred. No. 1.4e-34;
  Matches  191;  Conservative    0;  Mismatches   68;  Indels    4;  Gaps    3;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || ||||||||||| |   |||  || |||  |||||| |||
Db     276 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGACAATACTCTAGGG 335

Qy     148 ACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||| ||||||  |  ||||||| ||||| |||||||||| ||||||||
Db     336 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTGACTCTTGATACCAT 394

Qy     208 ATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTTTCCCGGCCTCCTATTGCCNGNAT 267
           |||| ||||   | |    |       ||||  |  ||   |||||||||   | | ||
Db     395 ATTTGTACCGAACACAGGAA--AGAAGAGTGGGAAATTGAAGGCCTCCTATAAACGGGAT 452

Qy     268 TGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTTCTGGACCGACCATCTATGGCT-G 326
           || |  | | | ||||||||||||||| |  |||||||||||| |||||||||||| |
Db     453 TGTTTTAGTGTTGGCAGTAATGTTGATATAGATTTTTCTGGACCAACCATCTATGGCTGG 512

Qy     327 TCTGNNTTGGCCTTTGAAGGTTG 349
           |||  |||||||| ||||| ||
Db     513 GCTGTGTTGGCCTTCGAAGGGTG 535
```

```
RESULT 3
AAZ50709
ID   AAZ50709 standard; DNA; 1393 BP.
XX
AC   AAZ50709;
XX
DT   31-MAY-2000  (first entry)
XX
DE   Nucleotide sequence of human fchd545 gene.
XX
KW   fchd545 gene; human; cardiovascular disease; oncogenic disorder;
KW   diabetic retinopathy; fibroproliferative disorder; artherosclerosis;
KW   TGF-beta signalling pathway; TGF; Transforming growth factor;
KW   pancreatic cancer; angiogenesis; inflammation; fibrosis; tumour growth;
KW   vascularisation; cytostatic; antidiabetic; opthalmological; ds.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             90..941
FT                   /*tag= a
FT                   /product= "fcdh545 protein"
XX
PN   WO200006206-A1.
XX
PD   10-FEB-2000.
XX
PF   30-JUL-1999;   99WO-US17394.
XX
PR   30-JUL-1998;   98US-0126640.
XX
PA   (MILL-) MILLENNIUM PHARM INC.
XX
PI   Falb DA;
XX
DR   WPI; 2000-205414/18.
DR   P-PSDB; AAY45015.
XX
PT   Identifying substances for ameliorating symptoms of fibroproliferative
PT   diseases or oncogenic related disorders -
XX
PS   Examples; Fig 3; 214pp; English.
XX
CC   The patent discloses methods for the treatment and diagnosis of
CC   cardiovascular diseases by novel human genes which are differentially
CC   expressed in different cardiovascular disease states. Compositions which
CC   can modify TGF-beta signalling pathway are identified by screening.
CC   These are used therapeutically to treat fibroproliferative and oncogenic
CC   disorders, especially TGF (Transforming growth factor)-beta related
CC   disorders, including diabetic retinopathy, artherosclerosis, pancreatic
CC   cancer, angiogenesis, inflammation, fibrosis, tumour growth and
CC   vascularisation. The present sequence is fchd545 gene which is down
CC   -regulated in endothelial cells subjected to shear stress can be used to
CC   design cardiovascular disease treatment strategies. Depending on whether
CC   the down-regulation has a pathogenic or protective effect treatment
CC   methods can be designed to increase or decrease the activity of the
CC   protein product of the gene.
XX
SQ   Sequence 1393 BP; 406 A; 269 C; 333 G; 385 T; 0 other;

  Query Match             37.4%;  Score 130.6;  DB 21;  Length 1393;
  Best Local Similarity   72.6%;  Pred. No. 1.4e-34;
  Matches  191;  Conservative    0;  Mismatches   68;  Indels    4;  Gaps    3;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || ||||||||||| |   |||  || |||  |||||| |||
Db     276 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGACAATACTCTAGGG 335

Qy     148 ACAGACCTTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||| ||||||  |  ||||||| ||||| |||||||||| ||||||||
Db     336 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTGACTCTTGATACCAT 394

Qy     208 ATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTTTCCCGGCCTCCTATTGCCNGNAT 267
           |||| ||||   | |    |       ||||  |  ||  |||||||||   | | ||
Db     395 ATTTGTACCGAACACAGGAA--AGAAGAGTGGGAAATTGAAGGCCTCCTATAAACGGGAT 452

Qy     268 TGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTTCTGGACCGACCATCTATGGCT-G 326
           || |  | | | ||||||||||||||| |  |||||||||||| |||||||||||| |
Db     453 TGTTTTAGTGTTGGCAGTAATGTTGATATAGATTTTTCTGGACCAACCATCTATGGCTGG 512

Qy     327 TCTGNNTTGGCCTTTGAAGGTTG 349
           |||  |||||||| ||||| ||
Db     513 GCTGTGTTGGCCTTCGAAGGGTG 535


RESULT 4
AAX57719
ID   AAX57719 standard; cDNA; 1414 BP.
XX
AC   AAX57719;
XX
DT   16-JUL-1999  (first entry)
XX
DE   Voltage-dependent anion channel CBMAAD07 coding sequence.
XX
KW   Human; voltage-dependent anion channel; CBMAAD07; antibody; antagonist;
KW   cancer; spontaneous abortion; infertility; ss.
XX
OS   Homo sapiens.
XX
PN   WO9921990-A1.
XX
PD   06-MAY-1999.
XX
PF   29-OCT-1997;   97WO-CN00118.
XX
PR   29-OCT-1997;   97WO-CN00118.
XX
PA   (UYSH-) UNIV SHANGHAI SECOND MEDICAL.
XX
PI   Wang Y,  Zhang Q;
XX
DR   WPI; 1999-303016/25.
DR   P-PSDB; AAY07222.
XX
PT   CBMAAD07, a human voltage-dependent anion channel protein, useful in
PT   the treatment and diagnosis of microsomal and neurological disorders
XX
PS   Claim 4; Page 7-8; 31pp; English.
XX
CC   This sequence represent the coding sequence for a novel human
CC   voltage-dependent anion channel designated CBMAAD07.  The protein,
CC   antibodies and (ant)agonists to it can be used for treating, e.g.
CC   cancer, spontaneous abortion and infertility.
XX
SQ   Sequence 1414 BP; 419 A; 270 C; 334 G; 391 T; 0 other;

  Query Match             37.4%;  Score 130.6;  DB 20;  Length 1414;
  Best Local Similarity   72.6%;  Pred. No. 1.5e-34;
  Matches  191;  Conservative    0;  Mismatches   68;  Indels    4;  Gaps    3;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || ||||||||||| |   |||  || |||  |||||| |||
Db     286 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGACAATACTCTAGGG 345

Qy     148 ACAGACCTTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||| ||||||  |  ||||||| ||||| |||||||||| ||||||||
Db     346 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTGACTCTTGATACCAT 404

Qy     208 ATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTTTCCCGGCCTCCTATTGCCNGNAT 267
           |||| ||||   | |    |       ||||  |  ||  |||||||||   | | ||
Db     405 ATTTGTACCGAACACAGGAA--AGAAGAGTGGGAAATTGAAGGCCTCCTATAAACGGGAT 462

Qy     268 TGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTTCTGGACCGACCATCTATGGCT-G 326
           || |  | | | ||||||||||||||| |  |||||||||||| |||||||||||| |
```

```
Db     463 TGTTTTAGTGTTGGCAGTAATGTTGATATAGATTTTTCTGGACCAACCATCTATGGCTGG 522

Qy     327 TCTGNNTTGGCCTTTGAAGGTTG 349
           |||  |||||||| ||||| ||
Db     523 GCTGTGTTGGCCTTCGAAGGGTG 545


RESULT 5
AAS74839
ID   AAS74839 standard; cDNA; 1062 BP.
XX
AC   AAS74839;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #10643.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG10652.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 1; SEQ ID No 10643; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1062 BP; 264 A; 264 C; 291 G; 243 T; 0 other;

  Query Match             34.7%;  Score 121;  DB 23;  Length 1062;
  Best Local Similarity   70.3%;  Pred. No. 2.6e-31;
  Matches  185;  Conservative    0;  Mismatches   74;  Indels    4;  Gaps    3;

Qy      88 ATGGGCTGCNACTATGG.CTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || |||||||| || |   |||  || |||  ||||||||||
Db     187 AAGGTCTGTAACTATGGACTTACCTTCACTCAAAAACGGAACACAGACAATACTCTTGGG 246

Qy     148 ACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||  ||||||  |  ||||| | ||||| ||||||| ||| ||||||||
Db     247 ACAGAAATCTCTTTGGAGAATAAG-TTGGCTAAAGGGTTGAAACTGAGTCTTGATACCAT 305

Qy     208 ATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTTTCCCGGCCTCCTATTGCCNGNAT 267
           |||  |||||  | |    |       ||||     ||   ||||||||||     | ||
Db     306 ATTGGTACCAAACACAGGAA--AGAAGAGTGGGGAATTGAAGGCCTCCTATAAATGGGAT 363

Qy     268 TGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTTCTGGACCGACCATCTATGGCT-G 326
           || |  | ' | ||||||||||||||| |  ||||||| ||||| ||||||||||||| |
Db     364 TGTTTTAGTGTTGGCAGTAATGTTGATCTAGATTTTTCCGGACCAACCATCTATGGCTGG 423

Qy     327 TCTGNNTTGGCCTTTGAAGGTTG 349
           |||  |||| |||||||| ||
Db     424 GCTGTGTTGGTCTTTGAAGGGTG 446


RESULT 6
AAS74840
ID   AAS74840 standard; cDNA; 1672 BP.
XX
AC   AAS74840;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #10644.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG10653.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 1; SEQ ID No 10644; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
```

```
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 1672 BP; 423 A; 376 C; 451 G; 422 T; 0 other;

  Query Match             30.1%;  Score 105;  DB 23;  Length 1672;
  Best Local Similarity   64.0%;  Pred. No. 1e-25;
  Matches  181;  Conservative    0;  Mismatches   98;  Indels    4;  Gaps    3;

Qy      66 GGGNGGCTANAGNCCNCATATCATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNG 125
           ||    ||| |  ||  |||| | |           |   |  |||||||||| |   |
Db     534 GGCAACCTAGAAACCAAATATAAGGTCTGTAACTATGGACTTACCCTTCACCCAGAAATG 593

Qy     126 GAGTACNGACGGTACTCT-TGGGACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGG 184
           ||  || |||  |||||| ||||||||  | | ||  |   |      ||||||| |||
Db     594 GAACACAGACAATACTCTAAGGGACAGAAATCTCTTTGGGAGAATAAGTTGGCTGAAGGG 653

Qy     185 TTNAAACTGACTCTCGATACCATATTTNTACCATNCNCTCCNATCCTTTTAGTGCCATTT 244
           || |||||||||| |||||||||||| ||||   | |    |       ||||  |  |
Db     654 TTGAAACTGACTCTTGATACCATATTTGTACCGAACACAGGAA--AGAAGAGTGGGAAAT 711

Qy     245 TCCCGGCCTCCTATTGCCNGNATTGNTNNANTCTCGGCAGTAATGTTGATNTNNATTTTT 304
           |   ||||||||||   | | |||| |  | | | |||||||||||||||| |  ||||||
Db     712 TGAAGGCCTCCTATAAACGGGATTGTTTTAGTGTTGGCAGTAATGTTGATATAGATTTTT 771

Qy     305 CTGGACCGACCATCTATGGCT-GTCTGNNTTGGCCTTTGAAGG 346
           ||||||| |||||||||||| | |||  |||||||| | | |
Db     772 CTGGACCAACCATCTATGGCTGGGCTGTGTTGGCCTTCGGAAG 814


RESULT 7
AAC01263
ID   AAC01263 standard; cDNA; 435 BP.
XX
AC   AAC01263;
XX
DT   06-OCT-2000  (first entry)
XX
DE   Human secreted protein 5' EST, SEQ ID NO: 1261.
XX
KW   Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW   gene therapy; chromosome mapping; ss.
XX
OS   Homo sapiens.
XX
PN   EP1033401-A2.
XX
PD   06-SEP-2000.
XX
PF   21-FEB-2000; 2000EP-0200610.
XX
PR   26-FEB-1999;   99US-0122487.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J,  Duclert A,  Giordano J;
XX
DR   WPI; 2000-500381/45.
DR   P-PSDB; AAG01257.
XX
PT   New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT   obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT   diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS   Claim 1; SEQ ID 1261; 71pp + CD-ROM; English.
XX
CC   The present sequence is one of a large number of 5' ESTs derived from
CC   mRNAs encoding secreted proteins. An ORF has been identified within the
CC   sequence. The 5' ESTs were prepared from total human RNAs or polyA+ RNAs
CC   derived from 30 different tissues. EST sequences usually correspond
CC   mainly to the 3' untranslated region (UTR) of the mRNA because they are
CC   often obtained from oligo-dT primed cDNA libraries. Such ESTs are not
CC   well suited for isolating cDNA sequences derived from the 5' ends of
CC   mRNAs and even in those cases where longer cDNA sequences have been
CC   obtained, the full 5' UTR is rarely included. 5' ESTs are derived from
CC   mRNAs with intact 5' ends and can therefore be used to obtain full length
CC   cDNAs and genomic DNAs. 5' ESTs are also used in diagnostic, forensic,
CC   gene therapy and chromosome mapping procedures. They are used to obtain
CC   upstream regulatory sequences and to design expression and secretion
CC   vectors.
XX
SQ   Sequence 435 BP; 127 A; 83 C; 114 G; 108 T; 3 other;

  Query Match             22.3%;  Score 77.8;  DB 21;  Length 435;
  Best Local Similarity   76.7%;  Pred. No. 1.3e-16;
  Matches   99;  Conservative    1;  Mismatches   28;  Indels    1;  Gaps    1;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || |||||||||| |   |||  || ||:  |||||| |||
Db     308 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGAYAATACTCTAGGG 367

Qy     148 ACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTGACTCTCGATACCAT 207
           |||||  | | ||| ||||||  |  ||||||| ||||| |||||||||||| ||||||||
Db     368 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTGACTCTTGATACCAT 426

Qy     208 ATTTNTACC 216
           |||| ||||
Db     427 ATTTGTACC 435


RESULT 8
AAS74836
ID   AAS74836 standard; cDNA; 473 BP.
XX
AC   AAS74836;
XX
DT   13-FEB-2002  (first entry)
XX
DE   DNA encoding novel human diagnostic protein #10640.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder; ss.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   P-PSDB; ABG10649.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 1; SEQ ID No 10640; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
```

```
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. AAS64197-AAS94564 represent novel human
CC   diagnostic coding sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence 473 BP; 148 A; 83 C; 120 G; 122 T; 0 other;

  Query Match             16.6%;  Score 57.8;  DB 23;  Length 473;
  Best Local Similarity   74.5%;  Pred. No. 1e-09;
  Matches   79;  Conservative    0;  Mismatches   26;  Indels    1;  Gaps    1;

Qy      88 ATGGGCTGCNACTATGGGCTCACCTTCACCCANANGNGGAGTACNGACGGTACTCTTGGG 147
           | || |||  ||||||| || ||||||||||| |   |||  || |||  |||||| |||
Db     258 AAGGTCTGTAACTATGGACTTACCTTCACCCAGAAATGGAACACAGACAATACTCTAGGG 317

Qy     148 ACAGACCTTTTTTGNGAGAATNTGCATGGCTGANGGGTTNAAACTG 193
           |||||  | | |||  ||||||  |  ||||||| |||||  ||||||
Db     318 ACAGAAATCTCTTGGGAGAATAAG-TTGGCTGAAGGGTTGAAACTG 362


RESULT 9
AAT08126
ID   AAT08126 standard; DNA; 26698 BP.
XX
AC   AAT08126;
XX
DT   13-AUG-1996  (first entry)
XX
DE   Mouse syndecan-1 gene.
XX
KW   Syndecan-1; ectodomain; tumour; cancer; therapy; proteoglycan;
KW   cell differentiation; ss.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   intron          1..4138
FT                   /*tag=  a
FT   misc_difference 1154
FT                   /*tag=  b
FT                   /note= "base n is not identified in the
FT                         specification"
FT   exon            4139..4444
FT                   /*tag=  c
FT                   /codon_start= 4378..4380
FT   intron          4445..22024
FT                   /*tag=  d
FT   exon            22025..23106
FT                   /*tag=  e
FT   intron          23107..23000
FT                   /*tag=  f
FT   exon            23001..23482
FT                   /*tag=  g
FT   intron          23483..23903
FT                   /*tag=  h
FT   exon            23904..24043
FT                   /*tag=  i
FT   intron          24042..24250
FT                   /*tag=  j
FT   exon            24251..26298
FT                   /*tag=  k
FT   intron          26299..26698
FT                   /*tag=  l
XX
PN   WO9534316-A1.
XX
PD   21-DEC-1995.
XX
PF   13-JUN-1995;   95WO-FI00344.
XX
PR   13-JUN-1994;   94US-0258862.
XX
PA   (JALK/) JALKANEN M.
PA   (MALI/) MALI M.
XX
PI   Jalkanen M,  Mali M;
XX
DR   WPI; 1996-049416/05.
DR   P-PSDB; AAR87001.
XX
PT   New syndecan ectodomain compsn. to reduce tumour growth - for
PT   delivery to extracellular environment for suppressing tumour growth
PT   in malignant and non-malignant tumours
XX
PS   Disclosure; Fig 2; 49pp; English.
XX
CC   A mouse gene (AAT08126) codes for syndecan-1 (AAR87001), a cell surface
CC   proteoglycan.  The ectodomain of syndecan-1 (amino acids 18-251)
CC   is capable of restoring a more differentiated morphology to tumour
CC   cells and to suppress the growth of malignant cells.  The DNA
CC   can be used for the prodn. of recombinant ectodomain, pref. using
CC   host cell of a similar cell type as that of the tumour.  The
CC   human syndecan-1 gene (AAT08125) has also been identified.
XX
SQ   Sequence 26698 BP; 5736 A; 6620 C; 7176 G; 7165 T; 1 other;

  Query Match             14.6%;  Score 51;  DB 17;  Length 26698;
  Best Local Similarity   66.0%;  Pred. No. 1.6e-06;
  Matches   66;  Conservative    0;  Mismatches   34;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
           |||||||||||||||| ||||||| ||  |  ||||| |   | |||||| |||||||||
Db    1519 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCGCCAGATCTC 1578

Qy      61 ATTGTGGGNGGCTANAGNCCNCATATCATGGGCTGCNACT 100
             || |||  || |     |  ||| |  | |   |  | |
Db    1579 GTTATGGATGGTTGTGAGCACCATGTGGTTGCTGGGAATT 1618


RESULT 10
AAQ67902
ID   AAQ67902 standard; DNA; 26700 BP.
XX
AC   AAQ67902;
XX
DT   08-DEC-1994  (first entry)
XX
DE   Syndecan gene.
XX
KW   Syndecan; enhancer; differentiation; tumor; therapy; hair growth; ss.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   intron          1..4377
FT                   /*tag=  a
FT   exon            4378..4443
FT                   /*tag=  b
FT   intron          4444..22025
FT                   /*tag=  c
FT   exon            22026..22106
FT                   /*tag=  d
```

```
FT   intron          22107..23000
FT                   /*tag= e
FT   exon            23001..23483
FT                   /*tag= f
FT   intron          23484..23904
FT                   /*tag= g
FT   exon            23905..24039
FT                   /*tag= h
FT   intron          24040..24250
FT                   /*tag= i
FT   exon            24251..24418
FT                   /*tag= j
FT   intron          24419..26700
FT                   /*tag= k
XX
PN   WO9412162-A.
XX
PD   09-JUN-1994.
XX
PF   01-DEC-1993;   93WO-FI00514.
XX
PR   01-DEC-1992;   92US-0988427.
XX
PA   (WAER/) WAERRI A M.
PA   (ALAN/) ALANEN-KURKI L M.
PA   (AUVI/) AUVINEN P O V.
XX
PI   Alanen-Kurki LM,  Auvinen POV,  Jaakkola PM,  Jalkanen MT;
PI   Leppaesm,  Mali MS,  Vihinen TA,  Waerri AM;
XX
DR   WPI; 1994-199926/24.
DR   P-PSDB; AAR55276.
XX
PT   Syndecan stimulation of cellular differentiation - useful for
PT   decreasing tumour growth used to promote hair growth
XX
PS   Disclosure; Page 22-39; 65pp; English.
XX
CC   The mouse syndecan gene enhancer, located 8-10 kb upstream from the
CC   initiation site, is given in AAQ67901.  Manipulation of the enhancer
CC   can be used either to slow or prevent tumor growth or to promote
CC   differentiation of specific cell types, e.g. epidermal cells to
CC   promote hair formation.  The complete mouse syndecan gene and its
CC   encoded protein are given in AAQ67902 and AAR55276.
XX
SQ   Sequence 26700 BP; 5742 A; 6559 C; 7233 G; 7165 T; 1 other;

  Query Match             14.6%;  Score 51;  DB 15;  Length 26700;
  Best Local Similarity   66.0%;  Pred. No. 1.6e-06;
  Matches   66;  Conservative    0;  Mismatches   34;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
           |||||||||||||||| |||||||  ||  |  |||||  |   | ||||||  |||||||||
Db    1519 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCGCCAGATCTC 1578

Qy      61 ATTGTGGGNGGCTANAGNCCNCATATCATGGGCTGCNACT 100
             || |||  || |      |  ||| |  | |   |  | |
Db    1579 GTTATGGATGGTTGTGAGCACCATGTGGTTGCTGGGAATT 1618


RESULT 11
AAV15946
ID   AAV15946 standard; DNA; 26700 BP.
XX
AC   AAV15946;
XX
DT   28-MAY-1998  (first entry)
XX
DE   Mouse syndecan gene sequence.
XX
KW   Syndecan; tumour suppression; tissue regeneration; enhancement;
KW   mouse; wound healing; ds.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   CDS             4378..24421
FT                   /*tag= a
FT                   /product= "syndecan protein"
FT                   /note= "contains introns"
FT   intron          1..4377
FT                   /*tag= b
FT                   /number= 1
FT   exon            4378..4443
FT                   /*tag= c
FT                   /number= 1
FT   intron          4444..22025
FT                   /*tag= d
FT                   /number= 2
FT   exon            22026..22106
FT                   /*tag= e
FT                   /number= 2
FT   intron          22107..23000
FT                   /*tag= f
FT                   /number= 3
FT   exon            23001..23483
FT                   /*tag= g
FT                   /number= 3
FT   intron          23484..23904
FT                   /*tag= h
FT                   /number= 4
FT   exon            23905..24039
FT                   /*tag= i
FT                   /number= 4
FT   intron          24040..24250
FT                   /*tag= j
FT                   /number= 5
FT   exon            24251..24418
FT                   /*tag= k
FT                   /number= 5
FT   intron          24422..26700
FT                   /*tag= l
FT                   /number= 6
XX
PN   US5726058-A.
XX
PD   10-MAR-1998.
XX
PF   07-JUN-1995;   95US-0472217.
XX
PR   07-MAR-1994;   94US-0206186.
PR   01-DEC-1992;   92US-0988427.
PR   01-DEC-1993;   93WO-FI00514.
PR   07-JUN-1995;   95US-0472217.
XX
PA   (ALAN/) ALANEN-KURKI L.
PA   (AUVI/) AUVINEN P.
PA   (JAAK/) JAAKKOLA P.
PA   (JALK/) JALKANEN M.
PA   (LEPP/) LEPPAE S.
PA   (MALI/) MALI M.
PA   (VIHI/) VIHINEN T.
PA   (WAER/) WAERRI A.
XX
PI   Alanen-kurki L,  Auvinen P,  Jaakkola P,  Jalkanen M;
PI   Leppae S,  Mali M,  Vihinen T,  Waerri A;
XX
DR   WPI; 1998-192770/17.
DR   P-PSDB; AAW47156.
XX
PT   New mouse syndecan gene sequences - useful for, e.g. suppressing
PT   tumour growth or promoting tissue regeneration in processes such as
PT   wound healing
XX
PS   Claim 2; Fig 2A-O; 48pp; English.
XX
```

```
CC   This is the mouse syndecan gene sequence. A 350 base pair fragment
CC   (AAV15948) of a purified 2196 base pair DNA molecule (AAV15947) enhances
CC   the expression of a gene operably linked to the promoter of the mouse
CC   syndecan gene in 3T3 cells following treatment with TGF- beta and bFGF
CC   when the fragment is operably linked to the promoter. A purified DNA
CC   molecule comprising a portion of the nucleotide residues 3538-3888 of
CC   the mouse syndecan genomic sequence suppresses expression of a gene
CC   operably linked to the promoter of the mouse syndecan gene in S115 cells
CC   treated with testosterone. Host cells can be transfected with vectors
CC   which contain either the enhancing or suppressing DNA molecules. The
CC   products may be used to alter the differentiated state of a host cell by
CC   altering its expression of syndecan, e.g. to induce and regulate
CC   syndecan expression, especially in cells which exhibit a malignant
CC   phenotype, regardless of the origin of transformation. The products can
CC   be used to produce therapeutics for suppressing tumour growth. They may
CC   enhance the syndecan expression in a host cell, by enhancing its gene
CC   transcription, especially in malignant or normal cells, and therefore
CC   promote tissue regeneration, especially in processes such as wound
CC   healing.
XX
SQ   Sequence 26700 BP; 5742 A; 6559 C; 7233 G; 7165 T; 1 other;

  Query Match             14.6%;  Score 51;  DB 19;  Length 26700;
  Best Local Similarity   66.0%;  Pred. No. 1.6e-06;
  Matches   66;  Conservative    0;  Mismatches   34;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
           |||||||||||||||| ||||||| ||  |  ||||| |   | |||||| |||||||||
Db    1519 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCGCCAGATCTC 1578

Qy      61 ATTGTGGGNGGCTANAGNCCNCATATCATGGGCTGCNACT 100
             || |||  || |     |  ||| |  | |   |  | |
Db    1579 GTTATGGATGGTTGTGAGCACCATGTGGTTGCTGGGAATT 1618


RESULT 12
AAV81283
ID   AAV81283 standard; DNA; 26700 BP.
XX
AC   AAV81283;
XX
DT   11-MAR-1999  (first entry)
XX
DE   Mouse syndecan-1 encoding DNA.
XX
KW   Syndecan-1; tumour; ectodomain; epithelial; mesenchymal; breast; mouse;
KW   endometrial tumour; prostatic tumour; oestrogenic; androgenic; steroid;
KW   glioma; myeloma; carcinoma; sarcoma; lymphoma; adenoma; ss.
XX
OS   Mus sp.
XX
FH   Key             Location/Qualifiers
FT   CDS             4378..24421
FT                   /*tag= a
FT                   /product= "mouse syndecan-1"
FT                   /note= "contains introns"
FT   exon            4378..4443
FT                   /*tag= b
FT                   /number= 1
FT   intron          4444..22025
FT                   /*tag= c
FT                   /number= 1
FT   exon            22026..22107
FT                   /*tag= d
FT                   /number= 2
FT   intron          22108..23001
FT                   /*tag= e
FT                   /number= 2
FT   exon            23002..23483
FT                   /*tag= f
FT                   /number= 3
FT   intron          23484..23904
FT                   /*tag= g
FT                   /number= 3
FT   exon            23905..24040
FT                   /*tag= h
FT                   /number= 4
FT   intron          24041..24251
FT                   /*tag= i
FT                   /number= 4
FT   exon            24252..2418
FT                   /*tag= j
FT                   /number= 5
XX
PN   US5851993-A.
XX
PD   22-DEC-1998.
XX
PF   07-JUN-1995;   95US-0488199.
XX
PR   07-JUN-1995;   95US-0488199.
PR   13-JUN-1994;   94US-0258862.
XX
PA   (BIOT-) BIOTIE THERAPIES LTD.
XX
PI   Jalkanen M,  Mali M;
XX
DR   WPI; 1999-104635/09.
DR   P-PSDB; AAW95198.
XX
PT   Reducing growth of tumour cells  - with ectodomain of syndecan
PT   applied to the extracellular environment to induce a more
PT   differentiated phenotype, particularly for hormone-dependent breast,
PT   endometrial or prostatic cancers
XX
PS   Disclosure; Fig 2A-M; 48pp; English.
XX
CC   The invention relates to a method of reducing the growth of tumour cells
CC   which comprises supplying a human syndecan ectodomain to the environment
CC   around the cells causing them to develop a more differentiated phenotype.
CC   The method is used to suppress tumour cells of epithelial, mesenchymal,
CC   pre-B or plasma cell origin, especially breast  endometrial or prostatic
CC   tumours, and particularly those responsive to oestrogenic or androgenic
CC   steroid. More generally it can be used to treat malignant or non-
CC   malignant tumours, particularly those characterised by loss of syndecan,
CC   e.g. gliomas, myelomas, carcinomas, sarcomas, lymphomas and adenomas. The
CC   present sequence represents the DNA sequence encoding a mouse syndecan-1.
XX
SQ   Sequence 26700 BP; 5742 A; 6559 C; 7233 G; 7165 T; 1 other;

  Query Match             14.6%;  Score 51;  DB 20;  Length 26700;
  Best Local Similarity   66.0%;  Pred. No. 1.6e-06;
  Matches   66;  Conservative    0;  Mismatches   34;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
           |||||||||||||||| ||||||| ||  |  ||||| |   | |||||| |||||||||
Db    1519 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCGCCAGATCTC 1578

Qy      61 ATTGTGGGNGGCTANAGNCCNCATATCATGGGCTGCNACT 100
             || |||  || |     |  ||| |  | |   |  | |
Db    1579 GTTATGGATGGTTGTGAGCACCATGTGGTTGCTGGGAATT 1618


RESULT 13
AAX85695/c
ID   AAX85695 standard; cDNA; 178 BP.
XX
AC   AAX85695;
XX
DT   06-SEP-1999  (first entry)
XX
DE   Novel cDNA sequence from a mouse blastocyst cDNA library.
XX
KW   Mouse; blastocyst; cDNA library; ss.
XX
OS   Mus sp.
```

```
XX
PN   JP11164691-A.
XX
PD   22-JUN-1999.
XX
PF   14-APR-1998;   98JP-0103115.
XX
PR   03-OCT-1997;   97JP-0271781.
XX
PA   (RIKA ) RIKAGAKU KENKYUSHO.
XX
DR   WPI; 1999-411831/35.
XX
PT   New blastocyst cDNA - useful for library construction
XX
PS   Claim 3; Page 26; 41pp; Japanese.
XX
CC   AAX85621-X85746 represent novel cDNA sequences that are isolated from a
CC   mouse blastocyst cDNA library. The cDNA library was constructed from
CC   C57Bl/6 mice. The sequence can be used as a source of primers, probes
CC   and complementary DNA sequences.
XX
SQ   Sequence 178 BP; 55 A; 42 C; 39 G; 42 T; 0 other;

  Query Match             14.3%;  Score 50;  DB 20;  Length 178;
  Best Local Similarity   72.0%;  Pred. No. 3..e-07;
  Matches   59;  Conservative    0;  Mismatches   23;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
          |||||||||||||||| ||||||| ||  |  ||||| |   | ||||||  ||||||||
Db     160 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCATCAGATCTC 101

Qy      61 ATTGTGGGNGGCTANAGNCCNC 82
           |||  ||| || |     || |
Db     100 ATTACGGGTGGTTGTGAGCCAC 79


RESULT 14
AAV84328/c
ID   AAV84328 standard; DNA; 5889 BP.
XX
AC   AAV84328;
XX
DT   26-APR-1999  (first entry)
XX
DE   Mouse A-myb genomic DNA.
XX
KW   A-myb gene; oncogene; transgenic animal; null mutant; stem cell;
KW   spermatogenesis; infertility; knockout mouse; animal model; ss.
XX
OS   Mus sp.
XX
PN   WO9846726-A1.
XX
PD   22-OCT-1998.
XX
PF   07-APR-1998;   98WO-US06896.
XX
PR   15-APR-1997;   97US-0043353.
XX
PA   (UTEM ) UNIV TEMPLE.
XX
PI   Hatton K,  Reddy EP,  Toscani A;
XX
DR   WPI; 1999-080737/07.
XX
PT   Transgenic non-human animal with disrupted A-myb locus in the genome
PT   - useful as model for male infertility and for studying
PT   spermatogenesis
XX
PS   Example 1; Page 51-55; 83pp; English.
XX
CC   This is the nucleotide sequence of a genomic clone of the mouse
CC   A-myb gene.  The gene was isolated by screening a lambda DASH mouse
CC   genomic library derived from the 129/J mouse strain, using a probe
CC   derived from the 5' end of an A-myb cDNA clone that encodes the
CC   DNA binding domain of the protein.  Positive clones that contained
CC   the 5.9 kb HindIII fragment were subcloned into pGEM 7Zf(+) plasmid
CC   vector.  The 5.9 kb fragment contains exons 3, 4 and 5 of the gene
CC   that code for the 5' end of the DNA binding domain of the protein.
CC   The genomic clone was deposited as NRRL B-21575.  The invention
CC   provides non-human animals in which expression of the A-myb gene is
CC   suppressed.  A transgenic non-human animal (especially a mouse), or
CC   stem cell, having a disrupted A-myb gene in the genome, is claimed.
CC   Also new are: (1) spermatogonia comprising recombinant DNA encoding
CC   a functional A-myb polypeptide; (2) a targeting vector for
CC   functionally disrupting an A-myb gene comprising a polynucleotide
CC   where one part of tl  polynucleotide contains a sequence homologous
CC   to sequences in or flanking an A-myb gene, and which, when
CC   integrated into the corresponding A-myb locus, functionally
CC   disrupts the A-myb gene; and (3) methods of restoring fertility to
CC   a subject who is infertile due to a defect in the A-myb locus, by
CC   administration of A-Myb or DNA encoding A-Myb.  Male A-myb -/-
CC   animals can be used as models for male infertility and for studying
CC   spermatogenesis.  They can be used to test 'rescue' constructs and
CC   other agents to treat male infertility.
XX
SQ   Sequence 5889 BP; 1828 A; 922 C; 1089 G; 2050 T; 0 other;

  Query Match             14.3%;  Score 50;  DB 20;  Length 5889;
  Best Local Similarity   72.0%;  Pred. No. 1.7e-06;
  Matches   59;  Conservative    0;  Mismatches   23;  Indels    0;  Gaps    0;

Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
          |||||||||||||||| ||||||| ||  |  ||||| |   | ||||||  ||||||||
Db    2148 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACCCCAGAAGAGGGCATCAGATCTC 2089

Qy      61 ATTGTGGGNGGCTANAGNCCNC 82
           |||  ||| || |     || |
Db    2088 ATTATGGATGGTTGTGAGCCAC 2067


RESULT 15
AAF63435
ID   AAF63435 standard; DNA; 6094 BP.
XX
AC   AAF63435;
XX
DT   14-MAY-2001  (first entry)
XX
DE   Murine CD39-L2 genomic DNA sequence.
XX
KW   Human CD39-like protein; apyrase; NDPase; platelet function inhibitor;
KW   myocardial infarction; cerebral ischaemia; angina; arterial thrombosis;
KW   cerebral artery thrombosis; platelet aggregation; inflammation;
KW   apoptosis; autoimmune disorder; neurological disorder;
KW   Alzheimer's disease; Parkinson's disease; cancer; CD39-L2; ds.
XX
OS   Mus sp.
XX
PN   WO200110205-A1.
XX
PD   15-FEB-2001.
XX
PF   09-AUG-2000; 2000WO-US21790.
XX
PR   09-AUG-1999;   99US-0370265.
PR   11-JAN-2000; 2000US-0481238.
PR   25-APR-2000; 2000US-0557800.
PR   26-MAY-2000; 2000US-0583231.
PR   30-JUN-2000; 2000US-0608285.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Ford J,  Mulero JJ,  Yeung G;
XX
```

DR WPI; 2001-147489/15.
XX
PT Polynucleotides encoding human CD39-like polypeptides, with apyrase
PT and/or NDPase activity, which are useful in the treatment of
PT pathological conditions caused by thrombosis (e.g. myocardial
PT infarction) and inflammatory disorders -
XX
PS Example 21; Page 106-108; 203pp; English.
XX
CC This invention relates to polynucleotides encoding human CD39-like
CC polypeptides with apyrase and/or NDPase activity. The polypeptides having
CC ATPDase, including NDPase, activity are useful for inhibiting platelet
CC function and can therefore be used in the prophylaxis or treatment of
CC pathological conditions caused by or involving thrombosis or excessive
CC coagulation or excessive platelet aggregation, such as myocardial
CC infarction, cerebral ischaemia, angina, arterial thrombosis, cerebral
CC artery thrombosis or intracardiac thrombosis, and conditions associated
CC with venous thrombosis. CD39-L4 and CD39-L2 polypeptides are useful in
CC modulating disease states (including platelet aggregation, inflammation
CC and apoptosis) associated with ADP or other purinergic signalling by
CC reducing the levels of NDPs. The polypeptides are also useful for
CC prophylaxis or treatment of inflammation related disorders, such as
CC disorders involving sepsis or systemic inflammatory response syndrome or
CC SIRS (and associated conditions such as fever, tachycardia, tachypnea,
CC cytokine overstimulation); autoimmune disorders such as thrombosis,
CC atherosclerosis, acute pancreatitis, dermat tis, including psoriasis,
CC cirrhosis, reperfusion injury, asthma, multiple sclerosis, arthritis;
CC neurological disorders including neurodegenerative diseases, epilepsy,
CC depression, Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, and amyotrophic lateral sclerosis; and cancer. The present
CC sequence represents the murine CD39 like protein CD39-L2 genomic DNA
CC sequence.
XX
SQ Sequence 6094 BP; 1589 A; 1471 C; 1445 G; 1504 T; 85 other;

Query Match 14.3%; Score 50; DB 22; Length 6094;
Best Local Similarity 72.0%; Pred. No. 1.7e-06;
Matches 59; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

```
Qy       1 TATTATATGTAAGTACNCTGTAGCAGTTGTNNGACACACTCTACGAGGGCNCCAGATCTC 60
          ||||||||||||||||| ||||||| ||  |  |||||  |   | ||||||  ||||||||
Db    3329 TATTATATGTAAGTACACTGTAGCTGTCTTCAGACACTCCAGAAGAGGGCATCAGATCTC 3388

Qy      61 ATTGTGGGNGGCTANAGNCCNC 82
           |||  ||| || |     || |
Db    3389 ATTACGGGTGGTTGTGAGCCAC 3410
```

Search completed: October 23, 2002, 22:23:09
Job time : 193 secs